Suven Life Sciences Limited announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, following a Board of Directors meeting held on January 29, 2026. The company reported a consolidated net loss of ₹101.92 crore for the quarter ended December 31, 2025, which represents a significant 160.53% increase in loss compared to the ₹39.12 crore loss in the same quarter last year (YoY). Sequentially, the net loss widened by 31.83% from ₹77.31 crore in the previous quarter ended September 30, 2025 (QoQ). Revenue from operations for the quarter stood at ₹2.81 crore, reflecting a 74.53% increase from ₹1.61 crore in the corresponding quarter of the previous year. However, on a quarter-on-quarter basis, revenue saw a sharp decline of 40.21% from ₹4.70 crore.

Suven Life Sciences is a clinical-stage biopharmaceutical company headquartered in Hyderabad, India, specializing in the discovery and development of novel therapeutics for central nervous system (CNS) disorders. The company’s research focus includes treatments for conditions such as Alzheimer’s disease, dementia, major depressive disorder (MDD), and sleep disorders. As a research-heavy organization, it frequently presents clinical data at global conferences, such as the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in late 2025. Notable investors in the company include ace investor Sunil Singhania’s Abakkus Asset Management and Prashant Jain’s 3P India Equity Fund. In January 2026, the company also announced leadership changes, including the appointment of Ms. Sangeetha Laxmi Kandari as Company Secretary and Compliance Officer.